Amplia Therapeutics (ASX:ATX) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 02, 2025)

View and export this data going back to 2013. Start your Free Trial

What is Amplia Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Amplia Therapeutics's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Amplia Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Amplia Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Amplia Therapeutics (ASX:ATX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Amplia Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (ASX:ATX) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

INNMF:USA

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics Headlines

No Headlines